Lexaria raises $5.9M by repricing warrants to extend runway into 2027
Lexaria Bioscience agreed immediate warrant exercises to raise about $5.9 million gross, cutting exercise prices, with H.C. Wainwright placing; proceeds plus an Australian tax rebate may carry operations and R&D into 2027.